Sildenafil: From angina to SARS-CoV-2
- 1 December 2021
- journal article
- review article
- Published by John Libbey Eurotext in Sexologies
- Vol. 30 (4), E149-E154
- https://doi.org/10.1016/j.sexol.2021.05.002
Abstract
Sildenafil was first examined as an alternative to nitrates for the management of angina pectoris and hypertension and eventually developed into an oral therapeutic agent used for the treatment of erectile dysfunction. There are appropriate indicators that PDE5 inhibitors may also modify the detrimental consequences of the immune system over-stimulation, supplying a new chance for their use in SARS-CoV2 patients. The use of sildenafil for the management of SARS-CoV2 has been suggested based on its several mechanisms of action and therapeutic effects and on the clinical features of SARS-CoV2 which similar to those of other pathologies treated with the PDE5 inhibitors. Here we review fundamental highlights in the enhancement of sildenafil for numerous scientific disorders and consider practicable new uses for this versatile drug. (C) 2021 Sexologies. Published by Elsevier Masson SAS. All rights reserved.Keywords
This publication has 51 references indexed in Scilit:
- Sildenafil Citrate 100 mg Starting Dose in Men with Erectile Dysfunction in an International, Double-Blind, Placebo-Controlled Study: Effect on the Sexual Experience and Reducing Feelings of Anxiety About the Next Intercourse AttemptThe Journal of Sexual Medicine, 2009
- Effect of sildenafil on acrolein-induced airway inflammation and mucus production in ratsEuropean Respiratory Journal, 2009
- Severe retinopathy of prematurity in infants <30 weeks' gestation in New South Wales and the Australian Capital Territory from 1992 to 2002Archives of Disease in Childhood: Fetal & Neonatal, 2007
- Effect of Sildenafil on Cardiac Performance in Patients With Heart FailureThe American Journal of Cardiology, 2005
- The Effect of Sildenafil on Pulmonary Embolism-Induced Oxidative Stress and Pulmonary HypertensionAnesthesia & Analgesia, 2005
- Oral Sildenafil Reduces Pulmonary Hypertension After Cardiac SurgeryThe Annals of Thoracic Surgery, 2005
- The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patientsKidney International, 2004
- Phosphodiesterase Type 5 as a Target for the Treatment of Hypoxia-Induced Pulmonary HypertensionCirculation, 2003
- Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionalityBritish Journal of Clinical Pharmacology, 2002
- A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunctionBritish Journal of Clinical Pharmacology, 2002